Study to Test if TEV-48574 is Effective in Relieving Asthma
- Study Title
- A Study to Test if TEV-48574 is Effective in Relieving Asthma
- Teva Identifier
- TV48574-AS-20031 | 2020-001927-15
- ClinicalTrials.gov Identifier
- NCT04545385
- Study Status
- Terminated
- Trial Condition(s)
- Asthma
- Interventions
- Drug: TEV-48574 | Drug: Placebo
- EudraCT Number
- 2020-001927-15
- Study Description
- The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult patients with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA). The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control. The duration of patient participation in the study is planned to be up to approximately 30 weeks.
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years and older
- Trial Duration
- August 25, 2020 - January 17, 2022
- Phase
- Phase 2
